Compare Abbott Laboratories (ABT) vs PubMatic Inc (PUBM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs PubMatic Inc — how do they compare? Abbott Laboratories trades at $95.76 (market cap $166.94B), while PubMatic Inc trades at $12.9 (market cap $619.32M). The key difference: Abbott Laboratories is far larger — about 269.6× PubMatic Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while PubMatic Inc pays none. Which is the better fit depends on your goals.
| ABT | PUBM | |
|---|---|---|
Market Cap | $166.94B | $619.32M |
Sector | Health | Technology |
52-Week High | $136.62 | $13.83 |
52-Week Low | $82.57 | $6.28 |
Enterprise Value | $193.69B | $516.83M |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
PubMatic trades at $13.32, down 1.7% over 24 hours, with a bullish technical signal from moving averages and a consensus price target of $17. The company reported a net loss of $14.46M in 2025 despite revenue of $282.93M, though it has beaten earnings expectations in recent quarters. Recent news highlights partnerships and product launches, such as the Creator Marketplace and AgenticOS integrations, aimed at driving growth in digital advertising.
The outlook is mixed: analyst sentiment is evenly split between Buy and Hold, with potential upside to the price target, but profitability concerns and a high P/E ratio of 132 pose risks. Investors should weigh the company's innovation in AI-driven ad tech against ongoing losses and competitive pressures in the programmatic advertising space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
